Retro Biosciences develops longevity biotechnology centered on cellular reprogramming, autophagy, and cell replacement therapies, with the stated goal of extending healthy human lifespan. The company was co-founded in 2021 by Joe Betts-LaCroix, Sheng Ding, and Matt Buckley, and Joe Betts-LaCroix serves as CEO. It launched with a $180 million seed round funded by Sam Altman, and later was reported to be raising a $1 billion Series A with Altman involved. Its headquarters are in Redwood City, California, and it also has an HQ listing in Redwood City on LinkedIn, though some directories place it in San Francisco.